Strategic Partnerships GTC operates a cooperative model that partners with laboratories, hospitals, oncology practices, and medical professionals. This presents opportunities to propose expanded network collaborations, co-branded testing programs, and joint ventures to scale access to comprehensive DNA and RNA profiling across more regions.

Expansion Momentum Recent facility expansion to Houston and ongoing presence at ASCO and ASH events indicate growth and market validation. Sales teams can target expanding healthcare networks, community cancer centers, and academic sites in Texas and expanding markets leveraging the credibility of new lab capabilities.

NGS and Biomarker Focus GTC emphasizes integrated DNA and RNA next-generation sequencing for hematologic neoplasms, solid tumors, and liquid biopsy. This opens cross-sell opportunities to providers seeking comprehensive molecular profiling, assay integration into CNSide CSF workflows, and real-world data partnerships.

Clinical Collaboration Past collaboration with Cota to integrate outcomes data with profiling data signals openness to data-driven partnerships. Potential upsell includes offering outcome-oriented analytics services, registry collaborations, and enhanced decision-support tools for treating physicians.

Industry Visibility Active participation in ASCO ASH and multiple abstracts demonstrates thought leadership and clinical relevance. Leverage this visibility to secure speaking engagements, pilot programs with cancer centers, and sponsorships or onboarding incentives for early-adopter clinics.